LIVERCARE
Prospective Observational Trial to Evaluate Quality of Life After Stereotactic Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma
Rekrutierend
NCT-Nummer:
NCT03253536
Studienbeginn:
Juli 2017
Letztes Update:
18.08.2017
Wirkstoff:
-
Indikation (Clinical Trials):
Carcinoma, Hepatocellular, Liver Neoplasms
Geschlecht:
Alle
Altersgruppe:
Erwachsene (18+)
Phase:
-
Sponsor:
Ludwig-Maximilians - University of Munich
Collaborator:
-
Studienleiter
Falk Roeder, MD Principal InvestigatorDepartment of Radiation Oncology, University Hospital, LMU Munich
Kontakt
Falk Roeder, MD Kontakt: Phone: +49 89 4400 73729 E-Mail: Falk.Roeder@med.uni-muenchen.de» Kontaktdaten anzeigen
Sabine Gerum, MD Kontakt: Phone: +49 89 4400 73729 E-Mail: Sabine.Gerum@med.uni-muenchen.de» Kontaktdaten anzeigen
Detailed Description: Prospective single arm, single center observational study to evaluate Quality of Life (Qol)
after stereotactic body radiotherapy (SBRT) for patients with hepatocellular cancer (HCC).
Patients will receive work-up, treatment and follow-up exclusively as routinely done except
additional quality of life measurements. This will include contrast-enhanced liver MRI or CT
and placement of fiducials if necessary. Radiation treatment planning will be based on
contrast-enhanced fourdimensional computed tomography (4D-CT) with abdominal compression.
Target volume definition will use an internal target volume (ITV) concept. Dose prescription
and fractionation will be prescribed individually based on lesion size, localisation,
movement and liver function according to institutional standards. Qol will be measured by
standardized and validated EORTC questionaires (QLQ C-30 and HCC 18) at baseline, at the end
of SBRT, during follow up at 6 weeks, 3,6,12,24,36,48 and 60 months.
Inclusion Criteria: - histologically or radiologically proven hepatocellular carcinoma - 1-3 lesions suitable for stereotactic radiation therapy - indication for SBRT according to multidisciplinary board evaluation - age >= 18 years - written informed consent for study participation - mental and verbal ability to complete standardized questionaires according to
assessment by investigator (physician)Exclusion Criteria: - age < 18 years - prior HCC specific systemic therapy - concurrent oncological systemic treatment - distant metastases - inadequate ability tobe compliant with the protocol or to complete standardizes
questionaires - inability to receive contrast-enhanced planning CT - missing ability to give informed consent - legal custody
Primary outcome: 1. Quality of life (Time Frame - 60 months):Quality of life Secondary outcome: 1. acute toxicity (Time Frame - 3 months):physician-related acute toxicity 2. late toxicity (Time Frame - 6, 12, 24, 36, 48, 60 months):physician-related late toxicity 3. response (Time Frame - 3 months):response to treatment according to imaging 4. local control (Time Frame - 60 months):absence of regrowth inside the treated lesion 5. hepatic control (Time Frame - 60 months):absence of regrowth or onset of new lesions inside the liver 6. distant control (Time Frame - 60 months):absence of extrahepatic progression 7. freedom from treatment failure (Time Frame - 60 months):absence of disease progression other than death 8. overall survival (Time Frame - 60 months):absence of death of any cause 9. pattern of recurrence (Time Frame - 60 months):pattern of recurrence 10. correlation Qol with acute toxicity (Time Frame - 3 months):correlation Qol with acute toxicity 11. correlation Qol with late toxicity (Time Frame - 6, 12, 24, 36, 48, 60 months):correlation Qol with late toxicity
observational:none (observational study)
Quelle: ClinicalTrials.gov
Sie können folgenden Inhalt einem Kollegen empfehlen:
"Prospective Observational Trial to Evaluate Quality of Life After Stereotactic Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma"
Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.
Die mit (* ) gekennzeichneten Angaben müssen eingetragen werden!